Table 1.

Renal presentation at baseline and clinical outcome

Patient No.123456
Baseline characteristics
    age (years)/gender (M/F)40/F59/M74/M71/F73/F64/M
    hypertensionNoYesYesYesYesYes
    serum creatinine (μmol/L)70150150298130280
    GFR ml/min per 1.73 m2854442143721
    protids/albumin (g/L)75/3260/3466/2869/3557/2464/29
    proteinuria (g/24 h)/Nephrotic syndrome0.5/No2/No3.3/Yes2.5/No5.1/Yes3.5/Yes
    haematuriaYesaYesYesYesYesaYes
    serum monoclonal IgIgG1κIgG1λIgGκIgGκIgGκIgGλ
    MIg concentration (g/L)3071618.921.34
    serum FLC (mg/L)NA988 (λ)NA525 (κ)102 (κ)NA
    kappa/lambda ratioNA0.03NA53.25.0NA
    LC proteinuriaκ (U + S)λ (U + S)κ (U)κ (U)κ (U + S)No
    bone marrow PC (%)4< 53 (dystrophic)7.553
Treatment
    time from diagnosis (months)4736720
    serum creatinine (μmol/L)450180500250
    GFR (ml/min per 1.73 m2) at the onset of treatment1234817
    chemotherapy regimenNo treatmentDexMel + DexCYC + DexBortezomib + DexNo treatment
Outcome
    ESRD (months from diagnosis)Yes (90)Yes (55)Yes (48)Yes (12)Yes (23)No
    serum Cr (μmol/L)290
    serum monoclonal IgG (g/l)23172714NA6
    serum FLC (mg/L)8800 (κ)NANA653 (κ)559 (κ)NA
    kappa/lambda ratio1392.4NANA31.436.3NA
    deathYesNoNoNoNoNo
    follow-up time (months)162946025364
  • a macroscopic hematuria.

    S, serum; U, urine; NA, not available; ESRD, end stage renal disease; FLC, free light chains; GFR, glomerular filtration rate; LC, light chains; MIg, monoclonal immunoglobulin, Dex, high-dose dexamethasone; Mel, melphalan; CYC, cyclophosphamide.